Serious adverse eventsm
NVX‐CoV2373 – Novavax showed no clear difference in serious adverse eventsm compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in serious adverse events: number experiencing 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Serious adverse events ( · individuals with moderate or severe COVID‐19
1 finding from 1 review
Serious adverse events ( · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Adverse events (serious) · carpal tunnel syndrome
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse events ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.66, 1.79]
890 participants
Low
Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 0.71 [0.41, 1.23]
894 participants
Low
Adverse events—'serious'—320/94 Duration of 10 months3 · COPD
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).
1 finding from 1 review
OR 1.17 [0.95, 1.45]
2476 participants
Low